To close in 2021, pharmaceutical companies set off a wave of listing again!

2021 has already ushered in the final battle, but rushing to the last train, there are still a number of pharmaceutical companies starting a wave of listings, including Pidtech, Shengnuo Pharmaceutical, and Maiwei Biotechnology
.
Sino Pharmaceutical was officially listed on the Hong Kong Stock Exchange.
On December 30th, Sino Pharmaceutical was officially listed on the Hong Kong Stock Exchange
.
As of the close on the 30th, the quoted price was 74 Hong Kong dollars per share, an increase of 17.
6%, and the current total market value was 6.
86 billion
.
Public information shows that Sinopharm was established in 2007 and is a technology drug company focusing on small nucleic acid interference drugs (RNAi)
.
The R&D pipeline mainly focuses on oncology, fibrotic diseases and diseases, viral diseases and cardiovascular and metabolic diseases.
The current company’s core products include STP705.
The indications include liver cancer, squamous cell carcinoma in situ (isSCC) and skin basal cell carcinoma (BCC).
); Another core product is STP707, and its indications include multiple solid tumors, metastatic cutaneous squamous cell carcinoma (cSCC), non-small cell lung cancer (NSCLC), liver cancer and other diseases
.
As of the time of listing, SinoPharm has completed 5 rounds of financing, with a total financing amount of nearly 270 million US dollars.
The institutions that participated in the previous rounds of financing have stepped up the steps of PricewaterhouseCoopers, Cornerstone Capital, Hongtao Capital, Longmen Capital, Rotary Stone Capital, Xianshi Hitomi capital, capital and other sun integrate
.
The application of Beide Pharmaceutical Science and Technology Innovation Board is accepted
.
This fundraising is planned to be used for the drug molecular building block regional center project, R&D laboratory project, and supplementary working capital
.
The prospectus shows that the company has long focused on the front end of the new drug research and development industry chain, relying on the core business of drug molecular building block research and development, production and sales, to provide new drug research and development institutions with novel structure and diversified drug molecular building blocks and scientific reagents.

.
Financial data shows that the company's revenue in 2018, 2019, 2020, and the first September of 2021 were 163 million yuan, 249 million yuan, 391 million yuan, and 427 million yuan; the corresponding net profit for the same period was -18,831,300 yuan respectively.
, -1102,500 yuan, 59,003,600 yuan, 66,701,900 yuan
.
Among them, it will turn losses into profits in 2020, and the net profit in the first three quarters of 2021 has exceeded that of the whole year of last year
.
The main reasons for the steady growth in performance include the good market prospects of the company's drug molecular building blocks and scientific reagent segments, coupled with the continuous improvement of the breadth and depth of its own products, and the company's active development of overseas markets
.
Maiwei Bio will soon be listed on the Sci-tech Innovation Board Innovative biopharmaceutical company Maiwei Bio will make an inquiry on December 29 and will soon successfully land on the Sci-tech Innovation Board
.
This time, Maiwei Biotechnology adopted the fifth set of listing standards for the listing on the Sci-tech Innovation Board
.
According to data, Maiwei Bio was established in May 2017.
Its main business is the research and development, production and sales of therapeutic biological products, specifically including human therapeutic monoclonal antibodies, bispecific/bifunctional antibodies and ADC drugs.
Antibody drugs and recombinant protein drugs including long-acting or specially modified cytokines
.
It is worth mentioning that although the fifth set of listing standards is adopted, the company has many highlights: strong R&D strength, with a cumulative R&D investment of 1.
113 billion yuan in the past three years, of which R&D investment in 2020 will reach 581 million yuan; secondly, as of At the end of 2020, Maiwei Biosciences has a total of 429 R&D personnel, 75% of whom are R&D personnel; in addition, the company expects that three products will be approved for the market in the next two years, and the corresponding products have a broad market prospect
.
Yahong Medicine sprints to go public on the Sci-tech Innovation Board On December 31, Yahong Medicine publicly issued shares and announced the results of the issuance on the Sci-tech Innovation Board.
The issue price was negotiated and determined to be 22.
98 yuan per share, and the number of shares to be issued was 110 million shares, all of which were New shares are issued, no old shares are transferred
.
It is reported that Yahong Pharmaceutical, established in 2010, is a subdivision company in the oncology drug research and development track, focusing on genitourinary system tumors and other major diseases.
It is a global innovative drug company
.
At present, the company’s core product with a relatively fast development process is APL-1202.
Two indications are currently undergoing Phase III clinical trials in China, including the second-line combined chemotherapy infusion for the treatment of recurrent non-muscular invasive bladder cancer; single-agent first-line treatment Untreated intermediate-risk bladder cancer
.
If the product is successfully approved for marketing in 2023, it is expected to become the first oral treatment for bladder cancer in China
.